letrozole has been researched along with Cancer of Endometrium in 36 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine device (LNG-IUD) or aromatase inhibitor (letrozole) in women with endometrial carcinoma or atypical endometrial hyperplasia who wished to preserve fertility." | 8.12 | Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia. ( Cao, D; Chen, J; Cheng, N; Peng, P; Shen, K; Wang, J; Yang, J; Yu, M; Zhang, Y; Zhou, H, 2022) |
| "To evaluate the effects of letrozole (Ltz) in carcinogen+estrogen-induced endometrial hyperplasia." | 7.83 | Effect of letrozole in carcinogen-plus-estrogen-induced endometrial hyperplasia in mice. ( Cândido, EB; Carneiro, MM; Carvalho-Macedo, AC; Lara, AC; Rocha, AL; Silva-Filho, AL; Vidigal, PV, 2016) |
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 7.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "Letrozole has been described as treatment for endometrial stromal sarcoma." | 6.46 | Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review. ( Dunton, CJ; Sylvestre, VT, 2010) |
| "Treatment with letrozole markedly inhibited the tumor growth; the inhibitor effect was further strengthened by combination with letrozole and curcumin." | 5.35 | Aromatase inhibitor letrozole in synergy with curcumin in the inhibition of xenografted endometrial carcinoma growth. ( Hao, Q; Hu, YL; Liang, YJ; Wang, JD; Wang, QL; Wu, YZ, 2009) |
| "Low-grade endometrial stromal sarcoma is generally an indolent tumor rich in estrogen and progesterone receptors." | 5.31 | Endometrial stromal sarcoma: objective response to letrozole. ( Aghajanian, C; Maluf, FC; Sabbatini, P; Schwartz, L; Xia, J, 2001) |
| "To evaluate the efficacy and safety of gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine device (LNG-IUD) or aromatase inhibitor (letrozole) in women with endometrial carcinoma or atypical endometrial hyperplasia who wished to preserve fertility." | 4.12 | Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia. ( Cao, D; Chen, J; Cheng, N; Peng, P; Shen, K; Wang, J; Yang, J; Yu, M; Zhang, Y; Zhou, H, 2022) |
| "To evaluate the effects of letrozole (Ltz) in carcinogen+estrogen-induced endometrial hyperplasia." | 3.83 | Effect of letrozole in carcinogen-plus-estrogen-induced endometrial hyperplasia in mice. ( Cândido, EB; Carneiro, MM; Carvalho-Macedo, AC; Lara, AC; Rocha, AL; Silva-Filho, AL; Vidigal, PV, 2016) |
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 3.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "Estrogen receptor (ER)-positive endometrial cancers (ECs) are characterized by phosphatidylinositol 3-kinase (PI3K) and receptor tyrosine kinase (RTK)/RAS/β-catenin (CTNNB1) pathway alterations in approximately 90% and 80% of cases, respectively." | 3.30 | A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer. ( Bouberhan, S; Bowes, B; Campos, S; Castro, C; Cheng, SC; Hayes, M; Horowitz, N; Kolin, DL; Konstantinopoulos, PA; Krasner, C; Lee, EK; Liu, JF; Matulonis, UA; Needham, H; Penson, RT; Polak, M; Sawyer, H; Shea, M; Wright, AA; Xiong, N; Yeku, O, 2023) |
| " One phase II trial of the potent orally bioavailable mTOR inhibitor, everolimus, in combination with letrozole demonstrated an unprecedented clinical benefit rate (CBR) of 40% and high objective response rate (RR) of 32% in hormone agnostic endometrial cancers." | 2.82 | Targeting the PI3K Pathway in Gynecologic Malignancies. ( Avila, M; Grinsfelder, MO; Pham, M; Westin, SN, 2022) |
| "Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2." | 2.80 | Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. ( Coleman, RL; Gershenson, DM; Jiang, Y; Johnston, T; Levenback, C; Lu, KH; Munsell, MF; Nowakowski, M; Ring, K; Slomovitz, BM; Soliman, PT; Yates, MS; Zhang, Q, 2015) |
| "Despite the selection of Type I endometrial cancer, which is more estrogen-dependent for its growth, modest clinical activity was observed in the metastatic setting." | 2.47 | Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers? ( Chu, QS; Steed, HL, 2011) |
| "Letrozole has been described as treatment for endometrial stromal sarcoma." | 2.46 | Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review. ( Dunton, CJ; Sylvestre, VT, 2010) |
| "Low-grade endometrial stromal sarcoma is a rare neoplastic growth in the uterine cavity, representing less than 1% of uterine tumors." | 1.62 | Complete remission of advanced low-grade endometrial stromal sarcoma after aromatase inhibitor therapy: a case report. ( Al Sharie, AH; Aleshawi, A; Alfaqih, M; Altal, OF; Halalsheh, OM; Shaban, S; Tashtush, N, 2021) |
| "This study aims to evaluate the effects and pregnancy outcomes of gonadotropin-releasing hormone agonist (GnRH agonist) combined with aromatase inhibitor (AI) in preserving the fertility of obese women with grade 1 endometrial cancer (EC)." | 1.51 | A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer. ( Cheng, N; Feng, F; Huang, H; Wang, J; Zhang, Z, 2019) |
| "Estrogen-dependent early stage endometrial cancer is relatively common in young women of reproductive age." | 1.48 | A successful live birth with in vitro fertilization and thawed embryo transfer after conservative treatment of recurrent endometrial cancer. ( Choi, YM; Kim, H; Kim, SH; Kim, SW; Ku, SY; Suh, CS, 2018) |
| "In a xenograft mouse model of endometrial cancer, concomitant AI administration suppressed the growth of endometrial cancer during ovarian stimulation." | 1.48 | Aromatase inhibitor use during ovarian stimulation suppresses growth of uterine endometrial cancer in xenograft mouse model. ( Ito, J; Kashiwagi, M; Kashiwazaki, N; Kawahara, T; Nakajima, M; Okamoto, N; Sugishita, Y; Suzuki, N; Takae, S; Uekawa, A, 2018) |
| "The aim of this study was to evaluate the efficacy and safety with gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine system or an aromatase inhibitor (letrozole) in young women with well-differentiated early endometrial carcinoma (EC) and complex atypical hyperplasia (CAH)." | 1.46 | Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women. ( Cao, D; Lang, J; Shen, K; Yang, J; Zhou, H, 2017) |
| "We compared the efficacy of endometrial cancer neoadjuvant treatment in 38 patients receiving nonsteroid (letrozol, anastrozol) or steroid (ekzemestan) aromatase inhibitors and 12 patients receiving metformin." | 1.37 | [Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer]. ( Bershteĭn, LM; Boiarkina, MP; Danilova, MA; Gershfel'd, ÉD; Khadzhimba, AS; Kovalevskiĭ, AIu; Maksimov, SIa; Meshkova, IE; Turkevich, EA, 2011) |
| "Treatment with letrozole markedly inhibited tumor growth; the inhibitory effect was further enhanced by the combination of letrozole and curcumin." | 1.36 | [Inhibiting effect of letrozole combined with curcumin on xenografted endometrial carcinoma growth in nude mice]. ( Hao, Q; Hu, YL; Liang, YJ; Wang, JD; Wu, YZ; Zhang, HM, 2010) |
| "Hec1A endometrial cancer cells (Hec1A/V) and Hec1A cells with siRNA knockdown of ER-alpha36 (Hec1A/RNAi) were treated with testosterone, ERK and Akt phosphorylation was assessed by Western blot analysis." | 1.35 | A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. ( Liang, XW; Lin, SL; Qiao, J; Schatten, H; Sun, QY; Wang, ZB; Wang, ZY; Yan, LY, 2009) |
| "Treatment with letrozole markedly inhibited the tumor growth; the inhibitor effect was further strengthened by combination with letrozole and curcumin." | 1.35 | Aromatase inhibitor letrozole in synergy with curcumin in the inhibition of xenografted endometrial carcinoma growth. ( Hao, Q; Hu, YL; Liang, YJ; Wang, JD; Wang, QL; Wu, YZ, 2009) |
| "Letrozole effect was relatively greater when such parameters as tumor-tissue aromatase level, estrogen concentration in vaginal smear and blood-cholesterol, FSH and LH levels were taken into consideration." | 1.33 | [Comparison of letrozole and exemestane used in non-adjuvant therapy of endometrial carcinoma]. ( Bershteĭn, LM; Gershfel'd, ED; Kovalevskiĭ, AIu; Maksimov, SIa; Meshkova, IE; Poroshina, TE; Thijssen, JH; Tsyrlina, EV; Vasil'ev, DA, 2005) |
| "Treatment with letrozole did not influence surgery." | 1.31 | Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. ( Berstein, L; Gamajunova, V; Gershfeld, E; Kovalevskij, A; Larionov, A; Maximov, S; Meshkova, I; Tsyrlina, E; Vasilyev, D, 2002) |
| "Low-grade endometrial stromal sarcoma is generally an indolent tumor rich in estrogen and progesterone receptors." | 1.31 | Endometrial stromal sarcoma: objective response to letrozole. ( Aghajanian, C; Maluf, FC; Sabbatini, P; Schwartz, L; Xia, J, 2001) |
| "Letrozole was found to be a highly potent inhibitor of tumor proliferation and more effective than tamoxifen." | 1.30 | Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. ( Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.78) | 18.2507 |
| 2000's | 12 (33.33) | 29.6817 |
| 2010's | 16 (44.44) | 24.3611 |
| 2020's | 7 (19.44) | 2.80 |
| Authors | Studies |
|---|---|
| Slomovitz, BM | 2 |
| Filiaci, VL | 1 |
| Walker, JL | 1 |
| Taub, MC | 1 |
| Finkelstein, KA | 1 |
| Moroney, JW | 1 |
| Fleury, AC | 1 |
| Muller, CY | 1 |
| Holman, LL | 1 |
| Copeland, LJ | 1 |
| Miller, DS | 1 |
| Coleman, RL | 2 |
| Chen, J | 2 |
| Wang, J | 3 |
| Cao, D | 3 |
| Yang, J | 3 |
| Huang, H | 2 |
| Pan, L | 1 |
| Xiang, Y | 1 |
| Konstantinopoulos, PA | 1 |
| Lee, EK | 1 |
| Xiong, N | 1 |
| Krasner, C | 1 |
| Campos, S | 1 |
| Kolin, DL | 1 |
| Liu, JF | 1 |
| Horowitz, N | 1 |
| Wright, AA | 1 |
| Bouberhan, S | 1 |
| Penson, RT | 1 |
| Yeku, O | 1 |
| Bowes, B | 1 |
| Needham, H | 1 |
| Hayes, M | 1 |
| Sawyer, H | 1 |
| Polak, M | 1 |
| Shea, M | 1 |
| Cheng, SC | 1 |
| Castro, C | 1 |
| Matulonis, UA | 1 |
| Yu, M | 1 |
| Zhou, H | 2 |
| Cheng, N | 2 |
| Zhang, Y | 1 |
| Peng, P | 1 |
| Shen, K | 2 |
| Avila, M | 3 |
| Grinsfelder, MO | 3 |
| Pham, M | 3 |
| Westin, SN | 3 |
| Colon-Otero, G | 1 |
| Zanfagnin, V | 1 |
| Hou, X | 1 |
| Foster, NR | 1 |
| Asmus, EJ | 1 |
| Wahner Hendrickson, A | 1 |
| Jatoi, A | 1 |
| Block, MS | 1 |
| Langstraat, CL | 1 |
| Glaser, GE | 1 |
| Dinh, TA | 1 |
| Robertson, MW | 1 |
| Camoriano, JK | 1 |
| Butler, KA | 1 |
| Copland, JA | 1 |
| Weroha, SJ | 1 |
| Altal, OF | 1 |
| Al Sharie, AH | 1 |
| Halalsheh, OM | 1 |
| Tashtush, N | 1 |
| Shaban, S | 1 |
| Alfaqih, M | 1 |
| Aleshawi, A | 1 |
| Lang, J | 1 |
| Kim, SW | 1 |
| Kim, H | 1 |
| Ku, SY | 1 |
| Suh, CS | 1 |
| Kim, SH | 1 |
| Choi, YM | 1 |
| Manuel, V | 1 |
| Dinato, FJ | 1 |
| Gutierrez, PS | 1 |
| Siqueira, SAC | 1 |
| Gaiotto, FA | 1 |
| Jatene, FB | 1 |
| Kawahara, T | 1 |
| Okamoto, N | 1 |
| Takae, S | 1 |
| Kashiwagi, M | 1 |
| Nakajima, M | 1 |
| Uekawa, A | 1 |
| Ito, J | 1 |
| Kashiwazaki, N | 1 |
| Sugishita, Y | 1 |
| Suzuki, N | 1 |
| Gibson, JAG | 1 |
| Thompson, WR | 1 |
| Konamme, S | 1 |
| Bhattacharya, S | 1 |
| Zhang, Z | 1 |
| Feng, F | 1 |
| Lu, XY | 1 |
| Yang, Y | 1 |
| Xu, H | 1 |
| Zeng, T | 1 |
| Zhang, ZZ | 1 |
| Jiang, Y | 1 |
| Yates, MS | 1 |
| Soliman, PT | 1 |
| Johnston, T | 1 |
| Nowakowski, M | 1 |
| Levenback, C | 1 |
| Zhang, Q | 1 |
| Ring, K | 1 |
| Munsell, MF | 1 |
| Gershenson, DM | 1 |
| Lu, KH | 1 |
| Yang, KH | 1 |
| Shin, JA | 1 |
| Jung, JH | 1 |
| Jung, HW | 1 |
| Lee, HR | 1 |
| Chang, S | 1 |
| Park, JY | 1 |
| Yi, SY | 1 |
| Yamaguchi, M | 1 |
| Erdenebaatar, C | 1 |
| Saito, F | 1 |
| Motohara, T | 1 |
| Miyahara, Y | 1 |
| Tashiro, H | 1 |
| Katabuchi, H | 1 |
| Lara, AC | 1 |
| Cândido, EB | 1 |
| Vidigal, PV | 1 |
| Rocha, AL | 1 |
| Carvalho-Macedo, AC | 1 |
| Carneiro, MM | 1 |
| Silva-Filho, AL | 1 |
| Dahhan, T | 1 |
| Fons, G | 1 |
| Buist, MR | 1 |
| Ten Kate, FJ | 1 |
| van der Velden, J | 1 |
| Barker, LC | 1 |
| Brand, IR | 1 |
| Crawford, SM | 1 |
| Bershteĭn, LM | 3 |
| Danilova, MA | 2 |
| Kovalevskiĭ, AIu | 3 |
| Gershfel'd, ED | 3 |
| Poroshina, TE | 2 |
| Tsyrlina, TE | 1 |
| Meshkova, IE | 3 |
| Turkevich, EA | 2 |
| Maksimov, SIa | 3 |
| Lin, SL | 1 |
| Yan, LY | 1 |
| Liang, XW | 1 |
| Wang, ZB | 1 |
| Wang, ZY | 1 |
| Qiao, J | 1 |
| Schatten, H | 1 |
| Sun, QY | 1 |
| Tzakas, E | 1 |
| Liu, S | 1 |
| Todd, RW | 1 |
| Redman, CW | 1 |
| Liang, YJ | 2 |
| Hao, Q | 2 |
| Wu, YZ | 2 |
| Wang, QL | 1 |
| Wang, JD | 2 |
| Hu, YL | 2 |
| Zhang, HM | 1 |
| Steed, HL | 1 |
| Chu, QS | 1 |
| Sylvestre, VT | 1 |
| Dunton, CJ | 1 |
| Jang, KS | 1 |
| Lee, WM | 1 |
| Kim, YJ | 1 |
| Cho, SH | 1 |
| Boiarkina, MP | 1 |
| Khadzhimba, AS | 1 |
| Berstein, L | 1 |
| Maximov, S | 1 |
| Gershfeld, E | 1 |
| Meshkova, I | 1 |
| Gamajunova, V | 1 |
| Tsyrlina, E | 1 |
| Larionov, A | 1 |
| Kovalevskij, A | 1 |
| Vasilyev, D | 1 |
| Tsyrlina, EV | 1 |
| Vasil'ev, DA | 1 |
| Thijssen, JH | 1 |
| Reich, O | 1 |
| Regauer, S | 1 |
| Bréchot, JM | 1 |
| Kamboucher, M | 1 |
| Brauner, M | 1 |
| Destable, MD | 1 |
| Duperron, F | 1 |
| Morère, JF | 1 |
| Azim, A | 1 |
| Oktay, K | 1 |
| Brodie, A | 1 |
| Lu, Q | 1 |
| Liu, Y | 1 |
| Long, B | 1 |
| Wang, JP | 1 |
| Yue, W | 1 |
| Maluf, FC | 1 |
| Sabbatini, P | 1 |
| Schwartz, L | 1 |
| Xia, J | 1 |
| Aghajanian, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Study of Abemaciclib in Combination With Letrozole or in Combination With Letrozole and Metformin in Recurrent or Persistent Endometrial Cancer[NCT03675893] | Phase 2 | 60 participants (Anticipated) | Interventional | 2018-12-24 | Recruiting | ||
| A Phase 2 Trial of Ribociclib (LEE011) and Letrozole in ER Positive Relapsed Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinomas, and Endometrial Cancers.[NCT02657928] | Phase 2 | 40 participants (Actual) | Interventional | 2016-07-08 | Completed | ||
| Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormon[NCT02730923] | Phase 1/Phase 2 | 72 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| A Phase II Study of Letrozole and RAD001 (Everolimus) in Patients With Advanced or Recurrent Endometrial Cancer[NCT01068249] | Phase 2 | 42 participants (Actual) | Interventional | 2010-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival time is defined as the time from registration to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT02657928)
Timeframe: From registration to death from any cause, assessed up to 2 years
| Intervention | months (Median) |
|---|---|
| Cohort A: Ovarian | 18.9 |
| Cohort B: Endometrial | 15.7 |
The percentage of patients who are progression-free at 12 weeks (PFS12) is defined as patients who are alive and progression free at 12 weeks. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT02657928)
Timeframe: At 12 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A: Ovarian | 52.6 |
| Cohort B: Endometrial | 57.9 |
Progression free survival (PFS) is defined as the time from the date of registration to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT02657928)
Timeframe: From registration to the first of either disease progression or death from any cause, assessed up to 2 years
| Intervention | months (Median) |
|---|---|
| Cohort A: Ovarian | 2.8 |
| Cohort B: Endometrial | 5.4 |
The number of patients with CA-125 response, defined as a 50% or greater reduction in baseline CA-125. (NCT02657928)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Overall (Cohort A + Cohort B) | 4 |
The number of patients with confirmed response (complete response or partial response) using Response Evaluation Criteria in Solid Tumors version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT02657928)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A: Ovarian | 3 |
| Cohort B: Endometrial | 3 |
The number of treatment-related Grade 3 or higher adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCT02657928)
Timeframe: Up to 30 days post-treatment
| Intervention | events (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 3 : Lymphopenia | Grade 3 : Leukopenia | Grade 3 : Neutropenia | Grade 3 : Febrile Neutropenia | Grade 3 : Fatigue | Grade 3 : Liver Enzymes | Grade 4 : Lymphopenia | Grade 4 : Leukopenia | Grade 4 : Neutropenia | Grade 4 : Febrile Neutropenia | Grade 4 : Fatigue | Grade 4 : Liver Enzymes | |
| Overall (Cohort A + Cohort B) | 5 | 8 | 6 | 0 | 2 | 3 | 1 | 0 | 0 | 1 | 0 | 0 |
OS is defined as the interval from first dose of study treatment to the date of death, irrespective of the cause of death; subjects still alive will be censored at the date of the last contact (NCT01068249)
Timeframe: from (1st treatment) to death or, for living patients, date of last contact, up to 24.4 months
| Intervention | months (Median) |
|---|---|
| RAD001 + Letrozole | 14 |
PFS is the time from first dose of study treatment until the first date of either objective disease progression or death due to any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 30% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Median PFS was estimated using the Kaplan-Meier method. (NCT01068249)
Timeframe: from study entry (1st treatment) to date of tumor progression, date of death, or, for patients alive without tumor progression, date of last follow-up, assessed up to 2 years
| Intervention | months (Median) |
|---|---|
| RAD001 + Letrozole | 3 |
Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). (NCT01068249)
Timeframe: Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| RAD001 + Letrozole | 28 |
(NCT01068249)
Timeframe: from study entry (1st treatment) to date of tumor progression, date of death, or, for patients alive without tumor progression, date of last follow-up, up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| RAD001 + Letrozole | 31 |
Objective response or stable disease rate monitored as patients accrue and are evaluated following the example of Thall and Simon. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT01068249)
Timeframe: at 8 weeks of treatment, then every 12 weeks, up to 2 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Complete Response (CR) | Partial Response (PR) | |
| RAD001 + Letrozole | 9 | 2 |
4 reviews available for letrozole and Cancer of Endometrium
| Article | Year |
|---|---|
Targeting the PI3K Pathway in Gynecologic Malignancies.
Topics: Endometrial Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Phosphatidy | 2022 |
Targeting the PI3K Pathway in Gynecologic Malignancies.
Topics: Endometrial Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Phosphatidy | 2022 |
Targeting the PI3K Pathway in Gynecologic Malignancies.
Topics: Endometrial Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Phosphatidy | 2022 |
Targeting the PI3K Pathway in Gynecologic Malignancies.
Topics: Endometrial Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Phosphatidy | 2022 |
Targeting the PI3K Pathway in Gynecologic Malignancies.
Topics: Endometrial Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Phosphatidy | 2022 |
Targeting the PI3K Pathway in Gynecologic Malignancies.
Topics: Endometrial Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Phosphatidy | 2022 |
Targeting the PI3K Pathway in Gynecologic Malignancies.
Topics: Endometrial Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Phosphatidy | 2022 |
Targeting the PI3K Pathway in Gynecologic Malignancies.
Topics: Endometrial Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Phosphatidy | 2022 |
Targeting the PI3K Pathway in Gynecologic Malignancies.
Topics: Endometrial Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Letrozole; Phosphatidy | 2022 |
Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers?
Topics: Aromatase Inhibitors; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Letrozole; Ne | 2011 |
Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Letroz | 2010 |
Collision of three histologically distinct endometrial cancers of the uterus.
Topics: Aged; Aromatase Inhibitors; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cystadenocarcinoma, Pap | 2012 |
4 trials available for letrozole and Cancer of Endometrium
| Article | Year |
|---|---|
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Endometrial Neoplasms; Estradiol; | 2022 |
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Endometrial Neo | 2023 |
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Endometrial N | 2020 |
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bayes Theorem; beta Catenin; Biomarkers, Tumo | 2015 |
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bayes Theorem; beta Catenin; Biomarkers, Tumo | 2015 |
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bayes Theorem; beta Catenin; Biomarkers, Tumo | 2015 |
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bayes Theorem; beta Catenin; Biomarkers, Tumo | 2015 |
28 other studies available for letrozole and Cancer of Endometrium
| Article | Year |
|---|---|
Low-grade endometrial stromal sarcoma with intracaval or intracardiac extension: a retrospective study of eight cases.
Topics: Adult; Endometrial Neoplasms; Female; Humans; Letrozole; Medroxyprogesterone; Retrospective Studies; | 2022 |
Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia.
Topics: Aromatase Inhibitors; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Gonadotropin-Releasing | 2022 |
Complete remission of advanced low-grade endometrial stromal sarcoma after aromatase inhibitor therapy: a case report.
Topics: Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurr | 2021 |
Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carcinoma, Endometrioid | 2017 |
A successful live birth with in vitro fertilization and thawed embryo transfer after conservative treatment of recurrent endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Conservative Treatment; Cryopreservation; Embryo Transfer; E | 2018 |
Cardiac metastatic endometrial stromal sarcoma 17 years after hysterectomy.
Topics: Antineoplastic Agents; Cardiac Surgical Procedures; Chemotherapy, Adjuvant; Endometrial Neoplasms; F | 2017 |
Aromatase inhibitor use during ovarian stimulation suppresses growth of uterine endometrial cancer in xenograft mouse model.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Endometrial Neoplasms; Estradiol; Female; Fert | 2018 |
Sister Mary Joseph nodule: a diagnostic challenge.
Topics: Abdomen; Aged; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Hysterectomy; Letrozole | 2018 |
A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.
Topics: Administration, Oral; Adult; Aromatase Inhibitors; Birth Rate; Endometrial Neoplasms; Female; Fertil | 2019 |
Synergistic in vitro anti-tumor effect of letrozole and everolimus on human endometrial carcinoma Ishikawa cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2014 |
A Case of Metastatic Low-Grade Endometrial Stromal Sarcoma Treated with Letrozole after Ovarian Ablation by Radiotherapy.
Topics: Ablation Techniques; Antineoplastic Agents; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; H | 2015 |
Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma.
Topics: Adult; Aromatase; Aromatase Inhibitors; Bone Density; Endometrial Neoplasms; Endometrial Stromal Tum | 2015 |
Effect of letrozole in carcinogen-plus-estrogen-induced endometrial hyperplasia in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinogenesis; Endo | 2016 |
The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study.
Topics: Adult; Aged, 80 and over; Aromatase Inhibitors; Combined Modality Therapy; Dose-Response Relationshi | 2009 |
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endo | 2009 |
[Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Bi | 2009 |
A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells.
Topics: Aromatase Inhibitors; Carcinoma; Cell Membrane; Endometrial Neoplasms; Enzyme Activation; Estrogen R | 2009 |
Hormonal therapy with letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS).
Topics: Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metas | 2009 |
Aromatase inhibitor letrozole in synergy with curcumin in the inhibition of xenografted endometrial carcinoma growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carcinoma; Cell Line, | 2009 |
[Inhibiting effect of letrozole combined with curcumin on xenografted endometrial carcinoma growth in nude mice].
Topics: Adenocarcinoma; Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Curcumin; Drug Synergism; Endometr | 2010 |
[Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Ar | 2011 |
Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.
Topics: Aged; Aromatase Inhibitors; Endometrial Neoplasms; Enzyme Inhibitors; Estradiol; Female; Follicle St | 2002 |
[Comparison of letrozole and exemestane used in non-adjuvant therapy of endometrial carcinoma].
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Endometrial Neoplasms; Female; Follicle | 2005 |
Hormonal treatment with aromatase inhibitors for patients with endometrial stromal sarcoma.
Topics: Aged; Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Letrozole; Nitriles; Sarcoma, End | 2005 |
[Pulmonary metastases from endometrial stromal sarcoma may benefit from hormone therapy].
Topics: Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Letrozole; Lung Neoplasms; Middle Aged; | 2007 |
Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma.
Topics: Antineoplastic Agents; Cryopreservation; Endometrial Neoplasms; Female; Fertility; Fertilization in | 2007 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Endometrial stromal sarcoma: objective response to letrozole.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Letrozole; Liver | 2001 |